Clinical Trial Update: Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study [Phase 1]

View source ↗

Summary

This notice describes a companion Phase 1 study for patients who completed participation in Regeneron's REGN2810 anti-PD-1 clinical trial, which has been withdr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Advanced Malignancies | Phase 1 | Status: WITHDRAWN